


IN THE CLAIMS

Please amend the claims as follows:


1. (Currently Amended) A method of reducing the viability of leukemia cells in a mammal sensitive to a 1-(R) compound of formula (II):



wherein R¹ is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R², R³, R⁴ and R⁵ are the same or different and are each hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R⁷ is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C₁-C₃)alkyl(CO), wherein each alkyl is substituted with 0-2 (C₁-C₄) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino;

comprising administering from about 50 mg to about 5000 mg of the (R)-compound of formula (II); or a salt thereof to a ~~human~~ cancer patient afflicted with a leukemia.

2. (Original) A method of increasing the susceptibility of leukemia cells in a mammal to a chemotherapeutic agent comprising contacting the cells with from about 50 mg to about 5000 mg of a compound of formula (II):



wherein R¹ is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R², R³, R⁴ and R⁵ are the same or different and are each hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R⁷ is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C₁-C₃)alkyl(CO), wherein each alkyl is substituted with 0-2 (C₁-C₄) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino; or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) The method of claim 1, comprising administering from about 100 mg to about 2500 mg ~~wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg.~~
4. (Currently Amended) The method of claim 2, comprising administering from about 100 mg to about 2500 mg ~~wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg.~~
5. (Currently Amended) The method of claim 1 wherein the compound of formula (II) is administered in a single dose.
6. (Currently Amended) The method of claim 2 wherein the compound of formula (II) is administered in a single dose.
7. (Currently Amended) The method of claim 1 wherein the compound of formula (II) is administered in divided doses.
8. (Currently Amended) The method of claim 2 wherein the compound of formula (II) is administered in divided doses.

-
9. (Currently Amended) The method of claim 1 further comprising administering wherein the compound of formula (II) to achieve a plasma concentration of the compound of formula (II) is from about 200 μM to about 1000 μM ~~400 μM~~ .
 10. (Currently Amended) The method of ~~claim 1~~ claim 2 further comprising administering wherein the compound of formula (II) to achieve a plasma concentration of the compound of formula (II) is from about 200 μM to about 1000 μM ~~400 μM~~ .
 11. (Original) The method of claim 1 wherein the leukemia is chronic lymphocytic leukemia.
 12. (Original) The method of claim 2 wherein the leukemia is chronic lymphocytic leukemia.
 13. (Currently Amended) The method of claim 1 wherein the ~~a~~ mammal is a human.
 14. (Currently Amended) The method of claim 2 wherein the ~~a~~ mammal is a human.
 15. (Cancelled) ~~The method of claim 14 wherein the mammal is undergoing treatment with a chemotherapeutic agent.~~
 16. (Original) The method of claim 1 wherein the compound of formula (II) or the salt thereof is administered orally.
 17. (Original) The method of claim 2 wherein the compound of formula (II) or the salt thereof is administered orally.
 18. (Original) The method of claim 1 wherein the compound of formula (II) is R(-)-etodolac.
 19. (Original) The method of claim 2 wherein the compound of formula (II) is R(-)-etodolac.

20. (Cancelled) ~~The method of claim 15 wherein compound of formula (II) is administered in combination with the chemotherapeutic agent.~~